Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study by Yujing Jin et al.
ORIGINAL RESEARCH
Adding Prandial Insulin to Basal Insulin Plus Oral
Antidiabetic Drugs in Chinese Patients with Poorly
Controlled Type 2 Diabetes Mellitus: An Open-Label,
Single-Arm Study
Yujing Jin . Xiaowei Sun . Xichen Zhao . Tiehong Zhu
Received: February 21, 2017
 The Author(s) 2017. This article is an open access publication
ABSTRACT
Introduction: There is relatively little data from
China on the efficacy and safety of adding
prandial insulin to basal insulin plus oral
antidiabetic drugs (OADs) in people with poorly
controlled type 2 diabetes mellitus (T2DM).
This study assessed the efficacy and safety of
basal insulin dose optimization followed by the
addition of prandial insulin in Chinese people
with T2DM achieving suboptimal glycemic
control with basal insulin and OADs.
Methods: In this open-label, single-arm study,
adults with T2DM receiving basal insulin plus
OADs underwent insulin dose optimization for
12 weeks. At week 12, subjects who achieved
fasting blood glucose (FBG) B6.5 mmol/L but
not HbA1c B7% added one injection of prandial
insulin at the main meal for an additional
24 weeks. Endpoints included mean HbA1c, the
achievement rate of HbA1c B7%, hypo-
glycemia, and other adverse events (AEs).
Results: A total of 120 subjects underwent basal
insulin optimization; At week 12, 110 study sub-
jects achieved FBGB6.5mmol/L, of whom66 did
not achieve HbA1c B7% and therefore initiated
prandial insulin. Three patients discontinued
prandial insulin due to dissatisfaction with treat-
ment outcome (n = 1), accidental injury (n = 1),
or personal reasons (n = 1). After 24 weeks of
basal-plus treatment, mean HbA1c significantly
decreased (8.06% to 7.17%; p\0.001), 65.1% of
subjects achieved HbA1c B7%, there was no
change in FBG (6.23–6.20 mmol/L; p = 0.118),
and mean post-prandial blood glucose decreased
(13.17–10.14 mmol/L; p\0.001). During basal-
plus treatment, three individuals experienced
hypoglycemia, and no significant change in the
mean subject weight was observed (73.2 vs.
73.3 kg; p = 0.379).
Conclusions: In people with T2DM who are
achieving suboptimal glycemic control with
basal insulin plus OADs, basal insulin dose
optimization followed by the addition of pran-
dial insulin improves glycemic control, is well
tolerated, and is associated with a low incidence
of hypoglycemia.
Keywords: Basal insulin; HbA1c; Insulin
glargine; Prandial insulin; Type 2 diabetes
INTRODUCTION
Intensive control of blood glucose is crucial to
minimizing the risk of disease-related compli-
cations in people with type 2 diabetes mellitus
(T2DM) [1]. Achieving the glycemic control
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
06F7F060022F228A.
Y. Jin  X. Sun  X. Zhao  T. Zhu (&)





targets recommended by the American Diabetes
Association (ADA) and other diabetes manage-
ment guidelines, typically glycated hemoglobin
(HbA1c) B7% [2, 3], significantly reduces the
incidence of micro- and macrovascular compli-
cations associated with T2DM [4, 5]. However,
due to the chronic and progressive nature of
T2DM, achieving glycemic control becomes
increasingly difficult as the disease advances.
If glycemic control cannot be achieved
through lifestyle changes and maximum toler-
ated doses of one or more oral antidiabetic
drugs (OADs), initiation of long-acting basal
insulin, with dose titration based on fasting
blood glucose (FBG) targets, is an effective and
safe option to intensify treatment [5–7]. How-
ever, for individuals who cannot achieve HbA1c
targets with basal insulin and OADs, questions
may arise regarding other treatment options
and how to introduce a further-intensified reg-
imen. Furthermore, previous studies demon-
strate that adding fast-acting prandial insulin to
decrease postprandial blood glucose (PBG) into
the normal range is an effective approach [8, 9].
Basal insulin plus prandial insulin (basal-
plus) therapy is considered to be a robust
treatment choice, and closely mimics endoge-
nous insulin secretion patterns; it uses a
long-acting basal insulin to control FBG and a
short-acting prandial insulin bolus to control
PBG. However, there are several barriers to
intensive basal-plus therapy, including frequent
blood glucose monitoring, multiple injections,
hypoglycemia, and weight gain, which have a
potential negative impact on the acceptance of
and compliance to these regimens as well as the
quality of life of individuals using them [10, 11].
Although premixed insulin is one option to
avoid some of these barriers, in clinical practice
not all patients using premixed insulin can
achieve adequate control of blood glucose due
to limited doses and the fixed insulin compo-
nent. In addition, premixed insulins have low
flexibility in terms of dose scheduling, which
can lead to hypoglycemia in people with more
erratic lifestyles and high FBG who do not eat
meals at regular times [8].
A previous study found that the addition of
one or two boluses of prandial insulin to a reg-
imen of OADs and once-daily basal insulin was
effective and more succinct than other options
[12]. In addition, observational data from China
show basal insulin use is often suboptimal, with
relatively low initial doses and inadequate dose
titration, and it was hypothesized that opti-
mization of basal insulin through adequate
titration before the addition of prandial insulin
may be an effective strategy to intensify treat-
ment and improve glycemic control without
unnecessarily adding therapeutics and thus
increasing the complexity of treatment regi-
mens [13, 14]. However, to the authors’
knowledge, no studies conducted in China have
examined the efficacy and safety of a treatment
strategy involving optimization of basal insulin
treatment followed by the addition of prandial
insulin. Therefore, this study aimed to investi-
gate the efficacy and safety of intensifying
hypoglycemic treatment through the titration
of basal insulin followed by the addition of a
single bolus of prandial insulin in Chinese
people with T2DM suboptimally controlled
with basal insulin plus OADs.
METHODS
Study Design and Subjects
This is an open-label, single-arm study consist-
ing of a screening phase (up to 2 weeks), insulin
glargine dose optimization for 12 weeks (phase
I, run-in period), and basal plus prandial insulin
treatment for 24 weeks (phase II, intensification
period).
Adults aged 30–75 years with T2DM were
recruited at the General Hospital of Tianjin
Medical University from March 2015 to July
2015. Eligible subjects had received insulin
glargine plus full tolerated doses of two or more
OADs for C6 months with suboptimal glycemic
control (FBG C6.5 mmol/L and HbA1c [7%).
Exclusion criteria included type 1 diabetes,
current or anticipated pregnancy, treatment
with prandial insulin in the past 6 months, or
any other multiple insulin injection (i.e., pre-
mixed or basal-plus insulin treatments),
unconscious hypoglycemia or frequent occur-
rence of hypoglycemic events, and severe car-
diovascular and cerebrovascular diseases or
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other critical diseases. All procedures followed
were in accordance with the ethical standards of
the responsible committee on human experi-
mentation (institutional and national) and with
the Helsinki Declaration of 1964, as revised in
2013. Written informed consent was obtained
from all study participants.
Treatment
Study subjects were initially receiving struc-
tured and tailored education based on their
lifestyle and dietary habits. All participants
received optimization of insulin glargine treat-
ment for 12 weeks during phase I; the insulin
glargine (Lantus, Sanofi, France) dose was
titrated to obtain an FBG target of B6.5 mmol/L.
At the end of phase I, patients who had
achieved FBG B6.5 mmol/L but not HbA1c B7%
initiated 24 weeks of prandial insulin (NovoR-
apid, Novo Nordisk, Denmark) before the
main mealtime, adjusted based on the dietary
habits of the study subjects. The main meal was
defined as the meal resulting in the highest PPG
value, determined from a seven-point daytime
blood glucose profile (before and 2 h after each
meal and at bedtime) conducted on three sep-
arate days in the week prior to initiation of
prandial insulin. Following the same method-
ology as used in the OSIRIS study [12], the ini-
tial dose of prandial insulin and dose titration
was based on mean PBG, and aimed to achieve a
PBG target of B7.8 mmol/L 2 h after each meal.
For safety, insulin secretagogues were discon-
tinued at the addition of prandial insulin and
were re-added only in patients with poor glu-
cose control after sufficient insulin titration.
OADs were continued as used before entry to
the study.
Outcomes
The primary outcome was change in mean
HbA1c from baseline to week 36. Secondary
outcomes included the proportion of patients
achieving HbA1c B7%, blood glucose profiles,
weight change, and insulin dose. Safety out-
comes included incidence of hypoglycemia and
other adverse events, including cardiovascular
and cerebrovascular events or diarrhea,
abdominal distension, dizziness, and vomiting.
Measurements
Blood glucose levels were measured using the
adjusted Contour TS Blood Glucose Meter and
Strip (Bayer Pharma, Germany). Patients com-
pleted self-blood monitoring four times a day
for at least three days per week, and FBG and
biochemical parameters were regularly mea-
sured in hospital every two weeks. HbA1c was
measured throughout the study period using
ion-exchange high-performance liquid chro-
matography (Bio-Rad, USA).
Hypoglycemia was defined as blood glucose
B3.9 mmol/L. Symptomatic hypoglycemia was
defined as an event with clinical symptoms
consistent with hypoglycemia, with or without
a confirmatory blood glucose measurement,
and associated with prompt recovery after oral
carbohydrate administration. Severe hypo-
glycemia was defined as an event with symp-
toms consistent with hypoglycemia in which
the patient required assistance, and the event
was confirmed by either blood glucose
\2.8 mmol/L or recovery after oral carbohy-
drate, intravenous glucose, or glucagon
administration.
Statistical Analysis
All data were analyzed using SPSS Windows
version 22.0 (IBM Analytics, USA). Descriptive
statistics were used to summarize all data.
Quantitative data in a normal distribution were
presented as mean (standard deviation [SD]),
while enumeration data were presented as a
ratio. Changes in parameters between baseline
and endpoint were evaluated using a
paired-samples t-test. An independent t-test was
used to compare differences in parameters
between subgroups, and the v2 test was used to
assess frequency distributions. p\0.05 (two
tailed) was considered to be statistically
significant.
Multiple linear regression analysis was used
to identify baseline parameters associated with
change in HbA1c at week 36. The variables
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included in the regression model were: age,
height, BMI, disease course, medication time,
insulin usage time, basal insulin dosage, base-
line HbA1c, FBG, and PBG.
RESULTS
Participants and Baseline Characteristics
A total of 126 individuals were screened and 120
were included in phase I (Fig. 1). At week 12,
110 study subjects had achieved FBG
B6.5 mmol/L, of whom 66 did not achieve
HbA1c B7% and were therefore included in
phase II. Of the 66 patients included in phase II,
three withdrew due to either patient dissatis-
faction with treatment outcome (n = 1), acci-
dental injury (n = 1), or personal reasons
(n = 1).
At baseline, the mean age of the study sub-
jects was 59.3 (8.7) years, 53.3% were female,
and the mean duration of T2DM was 6.6 (2.4)
years. The mean dose of basal insulin was
0.22 IU/kg/day, and 98.3%, 56.7%, and 74.2%
of subjects were receiving concomitant a-glu-
cosidase inhibitors, metformin, and insulin
secretagogues, respectively (Table 1). At base-
line, mean levels of HbA1c, FBG, and PBG were
8.83%, 9.28, and 14.47 mmol/L, respectively.
Basal Insulin Optimization from Baseline
to Week 12
After 12 weeks of basal insulin optimization, the
mean basal insulin dose had significantly
increased from 0.22 IU/kg/day at baseline to
0.36 IU/kg/day (p\0.001) (Table 1). Between
baseline and week 12, a significant decrease in
mean HbA1c (-1.43%), FBG (-3.04 mmol/L),
Fig. 1 Study ﬂow diagram. HbA1c glycated hemoglobin A1c
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and PBG (-3.58 mmol/L) was observed (all
p\0.001) (Fig. 2a and b). However, the mean
weight and BMI of the study subjects did not
change significantly during the 12-week basal
insulin optimization phase (Fig. 2c). Hypo-
glycemia was experienced by three patients
during the basal insulin optimization phase
(Table 1). The pattern of use of concomitant
OADs did not change between baseline and
week 12.
Basal Plus Prandial Insulin Treatment
from Week 12 to Week 36
For study subjects who achieved FBG
B6.5 mmol/L but did not reach HbA1c B7%
after 12 weeks of basal insulin optimization, the
addition of prandial insulin led to a significant
reduction in HbA1c of 0.89%, with a mean
HbA1c of 7.17% at week 36 (p\0.001) (Table 2)
(Fig. 3a). Furthermore, the mean FBG did not
change, and PBG decreased significantly, by
3.03 mmol/L (p\0.001), following 24 weeks of
basal-plus therapy (Fig. 3b). The mean total dose
of insulin at week 36 was 0.5 IU/kg/day. After
initiating prandial insulin treatment, 83.1% of
the patients receiving insulin secretagogues
ceased using these drugs, and the mean number
of OADs used also decreased from 2.71 to 2.12.
The proportion of patients completing the 24
weeks of basal- plus treatment was 95.5% (63/
66).
Three patients had symptomatic hypo-
glycemia events during the 24 weeks of basal-
plus treatment. There was no significant differ-
ence in the incidence of hypoglycemia before
and after treatment (1.7% vs. 2.5% v2 = 0.21;
p = 1.000) (Table 2). No severe hypoglycemia or
other severe adverse events were identified
during this phase of the study. After 24 weeks of
prandial insulin, the mean weight of patients
increased slightly without reaching statistical
significance versus week 12 (73.2 vs. 73.3 kg;
p = 0.379) (Table 2) (Fig. 3c).
Baseline Characteristics of Patients Who
Achieved HbA1c £7% Versus Those Who
Did Not
The proportion of patients who completed
24 weeks of basal-plus therapy and achieved
HbA1c B7% was 65.1% (41/63) (Table 3).
Table 1 Changes in clinical parameters from baseline to week 12 during basal insulin optimization
Parametersa Baseline (n5 120) Week 12 (n5 120) Mean difference (SD) p value
Weight (kg) 71.98 (6.39) 72.05 (6.38) 0.08 (0.81) 0.285
BMI (kg/m2) 25.82 (2.08) 25.85 (2.09) 0.03 (0.28) 0.271
FBG (mmol/L) 9.28 (1.34) 6.24 (0.29) 3.04 (1.32)* \0.001
PBG (mmol/L) 14.47 (2.63) 10.90 (2.85) 3.58 (1.79)* \0.001
HbA1c, (%) 8.83 (0.84) 7.40 (1.04) 1.43 (1.01)* \0.001
Dose of basal Insulin (IU/kg/day) 0.22 (0.05) 0.36 (0.06) 0.14 (0.04)* \0.001
Hypoglycemic events [n (%)] 2 (1.7) 3 (2.5) 1.000
OADs [n (%)]
a-Glucosidase inhibitor 118 (98.3) 118 (98.3)
Metformin 68 (56.7) 68 (56.7)
Insulin secretagogues 89 (74.2) 89 (74.2)
BMI body mass index, FBG fasting blood glucose, PBG postprandial blood glucose, OADs oral antidiabetic drugs
* p\0.01
a Parameters are summarized as mean (SD) unless speciﬁed
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Mean baseline HbA1c level, FBG level, and
PBG level were significantly higher among the
study subjects who did not achieve HbA1c
B7% than among those who did achieve this
target (differences: 0.94%, 1.08, and
2.48 mmol/L, respectively; all p values\0.05)
(Table 3). No significant difference in baseline
age, disease course, duration of insulin use,
baseline insulin dose, weight, height, BMI, or
use of OADs was observed between patients
who achieved HbA1c B7% and those who did
not.
Multiple Linear Regression of Factors
Associated with HbA1c at Week 36
In a stepwise multiple linear regression, baseline
HbA1c (B = 0.18, p = 0.022), PBG (B = 0.15,
p\0.001), and FBG (B = 0.08, p = 0.027) were
significantly associated with HbA1c at the end
of phase II (Table 4).
DISCUSSION
This study demonstrated that optimization of
basal insulin treatment followed by the addi-
tion of a single bolus of prandial insulin can
significantly improve rates of glycemic control
in patients with T2DM poorly controlled with
basal insulin plus OADs.
Our study found that optimizing basal insu-
lin treatment was effective for increasing rates
of glycemic control in patients with T2DM
poorly controlled with basal insulin plus OADs,
which is consistent with previous research [15].
Forty percent of the study subjects achieved
HbA1c B7% through a single optimized dose of
basal insulin, highlighting the importance of
following evidence-based guidelines for basal
insulin treatment, which recommend adequate
titration to meet FBG targets [2, 3]. In this
regard, several large observational studies have
shown that treatment with basal insulin in Asia
Table 2 Changes in clinical parameters after 24 weeks of basal-plus treatment
Parametersa Week 12 (n5 63) Week 36 (n5 63) Mean difference (SD) p value
HbA1c, (%) 8.06 (0.71) 7.17 (0.54) 0.89 (0.56)* \0.001
FBG (mmol/L) 6.23 (0.15) 6.20 (0.16) 0.03 (0.14) 0.118
PBG (mmol/L) 13.17 (1.72) 10.14 (2.20) 3.03 (1.53)* \0.001
Basal insulin dosage (IU/kg/day) 0.36 (0.06) 0.35 (0.05) 0.01 (0.02) 0.073
Prandial insulin dosage (IU/kg/day) 0 (0) 0.14 (0.04) 0.14 (0.04)* \0.001
Total insulin dosage (IU/kg/day) 0.36 (0.06) 0.50 (0.08) 0.14 (0.03)* \0.001
Weight (kg) 73.19 (6.82) 73.28 (6.90) 0.08 (0.76) 0.379
Number of OADs used 2.71 (0.46) 2.12 (0.42) 0.60 (0.61)* \0.001
OADs, n (%)
a-Glycosidase inhibitor 63 (100) 22 (34.9)
Metformin 18 (28.6) 63 (100)
Insulin secretagogue 59 (93.7) 10 (15.9)
Hypoglycemic events [n (%)] 2 (1.7) 3 (2.5) 1.000
Other adverse events [n (%)] 0 (0) 0 (0)
HbA1c glycated hemoglobin A1c, FBG fasting blood glucose, PBG postprandial blood glucose, OADs oral antidiabetic drugs
* p\0.01
a Parameters are summarized as the mean (SD) unless speciﬁed
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is currently suboptimal, with delayed initiation
of treatment and inadequate dose titration
[14, 16]. There are many potential factors lead-
ing to this situation, including fear of hypo-
glycemia, needle anxiety, and worries about
weight gain [17], as well as lack of patient edu-
cation, limited medical resources, inadequate
health care systems that make patient follow-up
difficult, and suboptimal blood glucose moni-
toring [18]. The present study shows that when
basal insulin is optimized correctly, it can lead
to improvements in glycemic control.
There is no clear consensus on the best
treatment intensification option for people with
T2DM poorly controlled with a combination of
basal insulin and OADs; current guidelines rec-
ommend the addition of prandial insulin as
basal-plus therapy, the use of premixed insulin,
or the addition of GLP1 receptor agonists [2, 3].
The results of this study suggest that, for people
with T2DM achieving suboptimal glycemic
control with basal insulin and OADs, it may be
better to first optimize the basal insulin dose to
achieve FBG targets by reducing the FBG level to
the normal range before considering the addi-
tion of other treatments. Indeed, previous
research investigating the addition of prandial
insulin—either at breakfast or the main meal-
time—to basal insulin with OADs for 24 weeks,
with no basal insulin optimization phase,
reported a mean reduction in HbA1c of 0.4%
[19]. In comparison, the reduction in HbA1c
observed with basal-plus in the present study
was relatively large (0.89%). However, apart
from the optimization of basal insulin, there
may have been several reasons for this
Table 3 Differences in baseline parameters between patients who achieved and did not achieve HbA1c B7% after 24 weeks
of basal-plus treatment
Parametersa HbA1c £7% (n5 41) HbA1c >7% (n5 22) Mean difference (SE) p value
Age (years) 63.76 (8.01) 61.64 (7.29) 2.12 (2.05) 0.306
Disease course (years) 7.30 (2.35) 7.60 (2.44) 0.30 (0.63) 0.641
Insulin usage time (years) 2.69 (1.70) 2.52 (0.92) 0.17 (0.39) 0.670
Basal insulin dosage (IU/kg/day) 0.35 (0.06) 0.37 (0.06) 0.02 (0.02) 0.126
Weight (kg) 72.71 (6.04) 73.73 (8.11) 1.02 (1.80) 0.574
Height (cm) 166.34 (7.72) 169.09 (7.91) 2.74 (2.06) 0.187
BMI (kg/m2) 26.28 (1.45) 25.39 (2.44) 0.89 (0.49) 0.076
FBG (mmol/L) 8.87 (1.42) 9.95 (1.75) 1.08 (0.41)* 0.010
PBG (mmol/L) 15.01 (1.06) 17.49 (1.42) 2.48 (0.32)** \0.001
HbA1c (%) 8.65 (0.76) 9.60 (0.82) 0.94 (0.21)** \0.001
Number of OADs 2.67 (0.48) 2.76 (0.44) 0.10 (0.14) 0.478
OADs (n)
a-Glycosidase inhibitor 42 21
Metformin 10 8
Insulin secretagogue 38 21
HbA1c glycated hemoglobin A1c, BMI body mass index, FBG fasting blood glucose, PBG fasting blood glucose, OADs oral
antidiabetic drugs, SE standard error
* p\0.05; **p\0.01
a Parameters are summarized as mean (SD) unless speciﬁed
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difference. Firstly, the diet and exercise of
patients in the present study was strictly and
comprehensively managed, facilitating the
control of PBG and overall blood glucose. Sec-
ondly, Chinese people usually eat one large
meal during the day. Thirdly, in contrast to the
previous study, prandial insulin was tailored
based on meal content, which may decrease the
level of PBG more effectively and lead to better
glycemic control [20, 21].
Results from the regression analysis demon-
strated that baseline HbA1c, FBG, and PBG were
associated with HbA1c levels at week 36, which
may aid the selection of patients who are likely
to achieve clinical benefit from the treatment
approach used in this study. These results were
partly consistent with a previous pooled analy-
sis which found that lower baseline HbA1c was
the best predictor of whether HbA1c targets
would be achieved with insulin glargine and
OADs [22]. Results from the present study and
those previous findings suggest that individuals
with T2DM who have relatively good glycemic
control before treatment are more likely to
achieve HbA1c targets. An inability to achieve
HbA1c targets may be due to poor self-man-
agement in diet and exercise, as well as rela-
tively poor islet cell function [23].
Although the basal-plus treatment approach
is well described in the literature and is widely
used clinically, this study is, to the author’s
knowledge, the first investigation of the basal
insulin optimization followed by basal-plus
approach conducted in China. Given that basal
insulin use in China and elsewhere in Asia has
been shown to be suboptimal, an investigation
of this two-step approach to treatment intensi-
fication is worthwhile [13, 14, 24]. In particular,
the 40% of subjects in the present study who
achieved HbA1c B7% through basal insulin
optimization show that the addition of prandial
insulin is not necessary for individuals who can
derive further benefit from basal insulin.
Several limitations of this study should be
noted. Firstly, this was a single-center study,
and the results may therefore lack generaliz-
ability. Secondly, the patient sample size was
relatively small, which limits the strength of the
conclusions that can be drawn. Finally, this was
a single-arm study, and no control group was
Table 4 Multiple linear regression of baseline factors associated with HbA1c after 24 weeks of basal-plus treatment




Constant 3.85 1.69 2.28 0.027
Age (years) 0.01 0.01 0.00 0.00 0.998
Height (m) 0.00 0.01 0.00 0.03 0.973
BMI (kg/m2) -0.05 0.03 -0.17 -1.64 0.107
Disease course (years) -0.01 0.03 -0.06 -0.50 0.624
Medication time (years) -0.02 0.03 -0.07 -0.56 0.582
Insulin usage time (years) 0.05 0.04 0.14 1.23 0.226
Basal insulin dosage (IU/kg/day) -0.39 0.97 -0.04 -0.40 0.692
Baseline HbA1c (%) 0.18 0.08 0.30 2.36 0.022*
FBG (mmol/L) 0.08 0.04 0.24 2.28 0.027*
PBG (mmol/L) 0.15 0.03 0.47 4.69 \0.001**
BMI body mass index, HbA1c glycated hemoglobin A1c, FBG fasting blood glucose, PBG postprandial blood glucose
* p\0.05; ** p\0.01
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included to allow comparison with other treat-
ment intensification approaches or a placebo.
This is a key limitation, as it has been shown
that recruitment to a clinical trial, regardless of
the intervention, leads to improved glycemic
control for individuals with T2DM [25]. As the
present study does not include a control arm, it
is difficult to separate the improvements in
glycemic control ascribable to the investigated
treatment strategy from those gained from
entering a clinical trial. However, the reduc-
tions in mean HbA1c observed in the present
study after 12 weeks of basal insulin
Fig. 2a–c Changes in a HbA1c, b FBG and PBG, and c
body weight between baseline and week 12 of basal insulin
optimization (n = 120), *p\0.01
Fig. 3a–c Changes in a HbA1c, b FBG and PBG, and
c body weight after 24 weeks’ treatment with basal-plus
during week 12 to 36 (n = 63), *p\0.01
Diabetes Ther
optimization and after 24 weeks of basal-plus
were larger than the reduction in HbA1c previ-
ously ascribed to the Hawthorne effect.
CONCLUSION
In conclusion, basal insulin optimization fol-
lowed by the addition of a single bolus of
prandial insulin may be an effective and safe
option for intensifying treatment for people
with T2DM poorly controlled with basal insulin
and OADs. Large-scale, multicenter, random-
ized control studies are warranted to validate
the results of this study.
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